Novo Nordisk acquired portfolio company Cardior Pharmaceuticals to strengthen its cardiovascular disease pipeline.
MAR 25, 2024
Cardior Pharmaceuticals is a pioneering biopharmaceutical company focused on discovering and developing RNA-based therapeutics to address the root causes of heart disease
Cardior Pharmaceuticals is a pioneering biopharmaceutical company focused on discovering and developing RNA-based therapeutics to address the root causes of heart disease. Their mission is to bring transformative treatments and diagnostics to patients worldwide, leveraging deep expertise in non-coding RNA biology to create innovative solutions for cardiac dysfunctions.